CareDx (CDNA)
(Delayed Data from NSDQ)
$9.72 USD
+0.45 (4.85%)
Updated May 3, 2024 04:00 PM ET
After-Market: $9.70 -0.02 (-0.21%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth C Momentum D VGM
Brokerage Reports
0 items in cart
CareDx, Inc. [CDNA]
Reports for Purchase
Showing records 1 - 20 ( 80 total )
Company: CareDx, Inc.
Industry: Medical Services
2023 Financial Results Reported; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: CareDx, Inc.
Industry: Medical Services
Positive Trend in Organ Donation; Patent Litigation Update; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: CareDx, Inc.
Industry: Medical Services
Optimized Entry and Exit Levels for CDNA 112123
Provider: Stock Traders Daily
Analyst: Research Department
Company: CareDx, Inc.
Industry: Medical Services
Test Volume Stabilizes in 3Q23; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: CareDx, Inc.
Industry: Medical Services
MolDX Revised Billing Article In Dispute; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: CareDx, Inc.
Industry: Medical Services
2Q23 Financial Results Reported; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: CareDx, Inc.
Industry: Medical Services
AlloSure Lung Receives Medicare Coverage; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: CareDx, Inc.
Industry: Medical Services
1Q23 Financial Results Reported; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: CareDx, Inc.
Industry: Medical Services
MolDX Revises Coverage For Solid Organ Transplantation Tests; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: CareDx, Inc.
Industry: Medical Services
Full-Year 2022 Financial Results Reported; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: CareDx, Inc.
Industry: Medical Services
Latest Advancements in Cellular Therapy Monitoring To Be Showcased; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: CareDx, Inc.
Industry: Medical Services
Published Guide Advocates Use of Noninvasive Surveillance for Heart Transplant; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: CareDx, Inc.
Industry: Medical Services
Preliminary 2022 Financial Results Reported; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: CareDx, Inc.
Industry: Medical Services
New Guidelines Support Earlier and Routine Use of HeartCare Tests; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: CareDx, Inc.
Industry: Medical Services
3Q22 Financial Results Reported; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: CareDx, Inc.
Industry: Medical Services
2Q22 Financial Results Reported; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: CareDx, Inc.
Industry: Medical Services
1Q22 Financial Results Reported; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: CareDx, Inc.
Industry: Medical Services
CDNA Wins False Advertising Case; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: CareDx, Inc.
Industry: Medical Services
Robust Top-Line Growth in 2021; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: CareDx, Inc.
Industry: Medical Services
Preliminary Full Year 2021 Results Reported; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y